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and medical conditions. Among all the potential comorbidities, co-existing anxiety disorders stand out due to
their high prevalence.
Aims: To determine the lifetime prevalence of comorbid anxiety disorders in bipolar affective disorder under the
care of psychiatric services through systematic review and meta-analysis.
Method: Random effects meta-analyses were used to calculate the lifetime prevalence of comorbid generalised
anxiety disorder, panic disorder, social anxiety disorder, speciﬁc phobia, agoraphobia, obsessive compulsive dis-
order and posttraumatic stress disorder in bipolar affective disorder.
Results: 52 studies were included in themeta-analysis. The rate of lifetime comorbidity was as follows: panic dis-
order 16.8% (95% CI 13.7–20.1), generalised anxiety disorder 14.4% (95% CI 10.8–18.3), social anxiety disor-
der13.3% (95% CI 10.1–16.9), post-traumatic stress disorder 10.8% (95% CI 7.3–14.9), speciﬁc phobia 10.8%
(95% CI 8.2–13.7), obsessive compulsive disorder 10.7% (95% CI 8.7–13.0) and agoraphobia 7.8% (95% CI 5.2–
11.0). The lifetime prevalence of any anxiety disorders in bipolar disorder was 42.7%.
Conclusions:Our results suggest a high rate of lifetime concurrent anxiety disorders in bipolar disorder. The diag-
nostic issues at the interface are particularly difﬁcult because of the substantial symptom overlap. The treatment
of co-existing conditions has clinically remained challenging.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar disorders with the prevalence rate of 4% are among themost
common psychiatric disorders (Ketter, 2010). It is considered to be the
sixth leading cause of disability worldwide due to its signiﬁcant eco-
nomic, social, familial and individual burdens (Woods, 2000). Lifetime
prevalence of bipolar disorder type I or type II (which includes at least
one hypo/manic episode during a lifetime) has been estimated at 2%
(Oldani et al., 2005). The relationship between bipolar disorder and
anxiety disorders can create a more difﬁcult course of treatment if co-
morbid (McIntyre et al., 2006). Studies suggest that the rate of anxiety
disorders in individuals with bipolar disorder is in fact greater than
those of the general population (Keller, 2006).; PTSD, posttraumatic stress
social anxiety disorder; DSM,
iﬁcation of Diseases.
l Health, The Oleaster Centre, 6
K.
).
. This is an open access article underBipolar disorder and anxiety disorders, including panic disorder,
generalised anxiety disorder (GAD), social anxiety disorder (SAD), spe-
ciﬁc phobia, agoraphobia, obsessive–compulsive disorder (OCD) and
posttraumatic stress disorder (PTSD) are psychiatric illnesses that indi-
vidually cause signiﬁcant mortality and morbidity, as reﬂected in sui-
cide rates (Allgulander and Lavori, 1991; Schneier et al., 1992; Osby
et al., 2001), substance abuse rates (Chengappa et al., 2000; Grant
et al., 2004), total medical burden (Klerman et al., 1991; Tolin et al.,
2008; Lauterback et al., 2005), economic costs (Souètre et al., 1994;
Wyatt and Henter, 1995) and quality of life (Wittchen et al., 1992;
Mendlowicz and Stein, 2000).
Clinical and epidemiological studies have reported lifetime preva-
lence rates for comorbid anxiety disorders in bipolar disorder of 50%
(Cassano et al., 1999; Pini et al., 1997; McElroy et al., 2001). The Epide-
miological Catchment Area study found the lifetime prevalence for
panic disorder in bipolar illness to be 20.8%, more than twice the rate
of 10% reported in patients with major depressive disorder (Pini et al.,
1997; Chen and Dilsaver, 1995a,b; Perugi et al., 2001). The frequency
of GAD at 30% in bipolar disorder is reported by two studies (Pini
et al., 1997; Young et al., 1993). The prevalence of comorbid socialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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47.2% (Kessler et al., 1997) and the prevalence rate of OCD has been
found to be between 3.2% and 35% (Pini et al., 1997; Perugi et al.,
2001; Szadoczky et al., 1998; Krüger et al., 1995). Although the associa-
tion between PTSD and bipolar disorder has been less extensively stud-
ied, the rate of comorbidity between these two conditions may exceed
by 40% (Musser et al., 1998).
Previous studies have suggested that multiple anxiety disorder co-
morbidities occur in a signiﬁcantminority of patientswith bipolar disor-
der. For example, Young et al. (1993) found multiple anxiety disorders
in 32% of bipolar disorder outpatients. Cassano et al. (1999) studied 77
inpatients presenting with severe mood disorders with psychotic fea-
tures, including bipolar I, and found the presence of one anxiety disor-
der in 34% of cases, while 14% of patients had two or three. Similarly,
Henry et al. (2003) studied 318 inpatients most of whom had bipolar I
disorder and found the rate of one or more lifetime comorbid anxiety
disorders to be 24% and 11%, respectively. The extent to which anxiety
and the presence of single or multiple anxiety disorders impact on
course and outcome in bipolar disorder has been studied only in a lim-
ited way (Ghoreishizadeh et al., 2009; Deckersbach et al., 2014).
Compared to those with uncomplicated bipolar disorder, this co-
occurrence with anxiety disorders is associated with increased suicide
attempts and ideation (Young et al., 1993; Simon et al., 2003; Lee and
Dunner, 2008; Frank et al., 2002; Angst et al., 2005), substance abuse
(Young et al., 1993; Simon et al., 2003; Lee and Dunner, 2008; Angst
et al., 2005; Toniolo et al., 2009), increased severity of mood episodes
(Frank et al., 2002; Angst et al., 2005; Toniolo et al., 2009; Gaudiano
and Miller, 2005), and more mood episodes. Young et al. (1993) and
Feske et al. (2000) also found a decrease in lithium responsiveness in
the presence of anxiety disorders. Other studies showed this combina-
tion has led to a longer recovery time (Feske et al., 2000; Otto et al.,
2006) and an earlier age at the onset of bipolar illness (Simon et al.,
2003; Lee and Dunner, 2008; Pini et al., 2006).
The co-occurrence of an anxiety disorder leads to a particularly difﬁ-
cult challenge in the treatment of bipolar illness since antidepressant
medication, the mainstay of pharmacologic treatments for anxiety,
may adversely alter the course of bipolar disorder. Furthermore, the
common co-occurrence of alcohol and substance use disorders with bi-
polar disorder, limits the utility of benzodiazepines. Identiﬁcation of
anxiety disorders in bipolar patients is important. The treatment plan
needs to balance the potential beneﬁts to harm of antidepressant ad-
ministration (El-Mallakh and Holliﬁeld, 2008) and benzodiazepines
(Brunette et al., 2003) administration.
In view of the presence of a high heterogeneity about the lifetime
prevalence of anxiety disorders in patients with bipolar disorder, we
aimed to quantitatively summarise the lifetime prevalence of robustly
deﬁned anxiety disorders in co-occurrence bipolar disorder (mainly
type I) in psychiatric inpatient and outpatient population.
2. Methods
2.1. Search Strategy and Selection Criteria
BN and AJM designed the review protocol and extraction form in ac-
cordance with the Preferred Reporting Items for Systematic Reviews
andMeta-Analyses (PRISMA) guidelines (Moher et al., 2009). A system-
atic search of PsycINFO, Medline, and CINAHL abstract databases was
done by BN, from 1992 to 2013.
We included studies with data for the lifetime comorbidity between
bipolar affective disorder and anxiety disorders among population of
patientswith bipolar affective disorder under the care of psychiatric ser-
vices, and we excluded the data from any community-based samples.
When it was possible, we only included the data from bipolar I studies
in order tominimise selection bias, as previous studies suggested differ-
ent prevalence of comorbidity between bipolar I and II with anxiety dis-
orders. Otherwise, we used the data of those studies, which had clearlyreportedno signiﬁcant differences in theirﬁndings regarding the type of
bipolar disorder. Hence, the term of ‘bipolar affective disorder’ in this
paper mainly indicates bipolar disorder type I. The included studies
were stratiﬁed into those comorbidities with all anxiety disorders and
those with a speciﬁc subtype of anxiety disorder, including GAD, panic
disorder, OCD, PTSD, SAD, speciﬁc phobia and agoraphobia. We exclud-
ed the data from any diagnoses of cyclothymia. In order tominimise se-
lection bias, we also excluded the community-based studies, as well as
the data from child and adolescent studies. We took extra care to ex-
clude duplicate publications (i.e. two or more studies investigating the
same sample) in order to avoid multiple or duplication bias (Fig. 1).3. Validity Assessment
3.1. Data Abstraction and Classiﬁcation
We extracted the primary data independently, which was reviewed
systematically. Based on the Cochrane Bias Method Group recommen-
dations, a four-point quality rating and a ﬁve-point bias risk were ap-
plied to each study. The quality rating score was used to assess the
study sample size, design, attrition, criterion method and method of
dealing with possible confounders using the following scale: 1 = low
quality; 2 = low-to-medium quality; 3 = medium-to-high quality;
and 4 = high quality. The bias rating score was similarly used to assess
possible bias in assessments of age, clinical setting with the following
score: 1 = low bias risk; 2 = low-to-medium bias risk; 3 = medium-
to-high bias risk; and 4 = high bias risk. Finally the sampling method
was assessed for each study, because this could affect the interpretation
of the comorbidity data. Any area of disagreement was resolved by BN
and AJM.3.2. Outcome Measures
We deﬁned the main outcomes of interests as the lifetime preva-
lence of comorbidity between bipolar affective disorder type I and anx-
iety disorders, as well as any speciﬁc type of anxiety disorders, deﬁned
by the DSM-III, DSM-III-R and DSM-IV, ICD-9 and ICD-10 criteria.3.3. Statistical Analysis
Overall effects estimates were calculated using the DerSimonian–
Laird meta-analysis. Heterogeneity was invariably moderate to high.
Therefore, a random effects meta-analysis was chosen over a ﬁxed
effects model with StatsDirect (version 2.7.7). For comparative and
sub-analyses, we needed a minimum of three independent studies
to justify analysis according to convention. The impact of heteroge-
neity on the pooled estimates of the individual outcomes of the
meta-analysis was assessed using Cochran's Q, a χ2 statistic. This
was used to test whether the differences between studies was due
to chance. A P value close to 1 suggests a high probability that the
observed heterogeneity was due to sampling error. We also used
the I² test to assess heterogeneity (thresholds were ≥80% = moderate
and ≥90% = high).
We examined the presence of publication bias with the Begg funnel
plot (Dear and Begg, 1992). In addition, we used the following three
tests to see if asymmetry in the funnel plot is caused by publication
bias. 1) Begg–Mazumdar test (Begg and Mazumdar, 1994), which
tests the inter-dependence of variance and effect sizewith a rank corre-
lation method. B) The Egger test (Egger et al., 1997), which tests for
asymmetry of the funnel plot. C) The Harbord test (Harbord et al.,
2006), which is similar to the Egger test but uses a modiﬁed linear re-
gression method to reduce the false-positive rates. We also used Spear-
man correlation with adjusted r² to assess the association between
linear variables.
Fig. 1. Trail ﬂow of selecting studies.
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We identiﬁed 1501 relevant articles, with 70 including lifetime prev-
alence of bipolar patientswith anxiety disorders' comorbiditywhowere
assessed using an interview-based diagnostic method (Fig. 1). A total of
18 out of 70 studies were excluded because they either contained insuf-
ﬁcient data for analysis (16 studies) or were a review article. One study
was excluded as it was conducted on a child and adolescent population
with the mean age of 12.7 years old (Sala et al., 2010). We identiﬁed 52
relevant articles including 13,656 individualswith established diagnosis
of bipolar disorder with lifetime comorbid anxiety disorders, including
GAD, PTSD, SAD, speciﬁc phobia, agoraphobia, panic disorder and OCD
(Table 2). The majority of the studies (32 out of 52) were carried out
in outpatient clinic populations and 13 studies were conducted in inpa-
tient settings. Seven studies included both inpatient and outpatient in-
dividuals. 36 studies used consecutive samples, whereas a further 16
studies used convenience sampling method (Table 2). Data extraction
is shown in Fig. 1 in accordance with the Quality of Reporting of Meta-
analyses Guidelines (Moher et al., 1999).
From the identiﬁed articles, wewere unable to demonstrate the total
comorbidity between bipolar disorder and all anxiety disorders conﬁ-
dently, as some of the individual studies examined only one or two sub-
types of the anxiety disorders, e.g. GAD or OCD. However, in twenty-
nine out of ﬁfty-two articles which including 3064 individuals, we
were able to extract the total lifetime comorbidity with anxiety disor-
ders (Fig. 2). Meta-analysis pooled prevalence of lifetime comorbidity
of any anxiety disorders in bipolar disorder was 42.7% (95% CI 37.5–
48.0)with high heterogeneity (Table 1). It should be noted that a higher
prevalence rate of comorbid anxiety disorders is mainly due to the fact
that some individuals have had multiple identiﬁed anxiety disorder
conditions.4.1. Lifetime GAD Comorbidity in Bipolar Disorder
We identiﬁed 30 relevant articles which including 892 individuals
with lifetime comorbid GAD in bipolar affective disorder (Fig. 3). All
studies were carried out in either psychiatric outpatient clinics or inpa-
tient settings. The lifetime prevalence of GAD in individual studies
ranged from 1.3% (95% CI 0.03–7.0) (Strakowski et al., 1992) to 56.8%
(95% CI 46.2–66.9) (Castro e Couto et al., 2012). Meta-analysis pooled
prevalence of comorbid GAD was 14.4% (95% CI 10.8–18.3) with high
heterogeneity (Table 1 and Fig. 3). Infrequent reports of very low or
very high prevalence in small studies suggest possible publication
bias, as such studies are prone to take longer to be published; or theresults not conforming to the desired outcomemay not even be report-
ed (Rothman and Greenland, 1998).
4.2. Lifetime PTSD Comorbidity in Bipolar Disorder
We identiﬁed 25 relevant articles which including 1185 individuals
with PTSD lifetime comorbidity in bipolar affective disorder (Fig. 4).
All studies were carried out in either psychiatric outpatient clinics or in-
patient settings. The lifetime prevalence of PTSD in individual studies
ranged from none (Koyuncu et al., 2010) to 28.3% (95% CI 23.5–33.5)
(Bauer et al., 2005). Meta-analysis pooled prevalence of comorbid
PTSD was 10.8% (95% CI 7.3–14.9) with high heterogeneity (Table 1
and Fig. 4).
4.3. Lifetime SAD Comorbidity in Bipolar Disorder
We identiﬁed 32 relevant articles which including 921 individuals
with lifetime social anxiety disorder comorbidity in bipolar affective
disorder (Fig. 5). All studies were carried out in either psychiatric
outpatient clinics or inpatient settings. The lifetime prevalence of
social anxiety disorder in individual studies ranged from none (Pini
et al., 1997) to 38.7% (95% CI 26.6–51.9) (Fracalanza et al., 2011).
Meta-analysis pooled prevalence of comorbid social anxiety disorder
was 13.3% (95% CI 10.1–16.9) with high heterogeneity (Table 1 and
Fig. 5).
4.4. Lifetime Agoraphobia Comorbidity in Bipolar Disorder
We identiﬁed 11 relevant articles which including 251 individ-
uals with lifetime agoraphobia comorbidity in bipolar affective dis-
order (Fig. 6). All studies were carried out in either psychiatric
outpatient clinics or inpatient settings. The lifetime prevalence of
agoraphobia in individual studies ranged from 1.4% (95% CI 0–7.7)
(Altindag et al., 2006) to 24.0% (95% CI 9.3–45.1) (Sharma et al.,
1995). Meta-analysis pooled prevalence of comorbid agoraphobia
was 7.8% (95% CI 5.2–11.0) with high heterogeneity (Table 1 and
Fig. 6).
4.5. Lifetime Speciﬁc Phobia Comorbidity in Bipolar Disorder
We identiﬁed 26 relevant articles which including 448 individuals
with lifetime speciﬁc phobia comorbidity in bipolar affective disorder
(Fig. 7). All studies were carried out in either psychiatric outpatient
clinics or inpatient settings. The lifetime prevalence of speciﬁc phobia
in individual studies ranged from 0.8% (95% CI 0–4.5) (Chang et al.,
Fig. 2. Lifetime anxiety disorder comorbidity in bipolar disorder.
Table 1
Summary of lifetime prevalence of comorbid anxiety disorders in bipolar I, publication bias and heterogeneity ﬁndings.
Comorbid anxiety
disorders
Number
of studies
Total number
of cases
Lifetime prevalence
(95% CI)
Cochran Q
(P value)
Heterogeneity I²
(95% CI)
Begg-Mazumdar
(P value)
Egger
(95% CI)
Harbord (95% CI)
Anxiety disorders 29 3064 42.7% (37.5–48.0) 575.62 (P b 0.0001) 95.1% (94.2–95.8) 0.167 (0.210) 5.1 (2.1–8.0) 4.3 (1.4–7.2)
Panic disorder 45 1537 16.8% (13.7–20.1) 775.97 (P b 0.0001) 94.2% (93.3–94.9) 0.273 (0.007) 4.0 (2.4–5.7) 2.6 (0.2–5.0)
Generalised anxiety disorder 30 892 14.4% (10.8–18.3) 478.00 (P b 0.0001) 93.9% (92.7–94.9) 0.149 (0.256) 4.0 (1.8–6.1) 1.1 (−1.6–3.9)
Posttraumatic stress disorder 25 1185 10.8% (7.3–14.9) 678.29 (P b 0.0001) 96.5% (95.9–96.9) 0.193 (0.185) 3.9 (0.6–7.2) −1.3 (−4.4.1.7)
Obsessive compulsive disorder 43 808 10.7% (8.7–13.0) 424.42 (P b 0.0001) 90.1% (87.9–91.7) 0.229 (0.030) 3.4 (2.4–4.3) 3.7 (1.9–5.4)
Social anxiety disorder 32 921 13.3% (10.1–16.9) 553.76 (P b 0.0001) 94.4% (93.3–95.2) 0.209 (0.095) 4.0 (2.3–5.8) 2.9 (0.1–5.7)
Speciﬁc phobia 26 448 10.8% (8.2–13.7) 185.39 (P b 0.0001) 86.5% (81.7–89.6) 0.286 (0.041) 2.7 (0.9–4.4) 1.3 (−1.1–3.7)
Agoraphobia 11 251 7.8% (5.2–11.0) 101.16 (P b 0.0001) 90.1% (84.8–93) 0.381 (0.121) 3.0 (0.7–5.3) 4.7 (0.3–9.0)
Heterogeneity interpretation: Cochrane test: a P value of b.1 is considered signiﬁcant for the presence of statistical heterogeneity. I²: greater than 80%=moderate, I² greater than 90%=high.
Publication bias interpretation: Begg–Mazumdar test: P value b 0.05 is considered signiﬁcant and indicates a presence of publication bias. Egger and Harbord tests: if the intercept differs
signiﬁcantly from zero, this may indicate that publication bias is present.
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Fig. 3. Lifetime GAD comorbidity in bipolar disorder.
1409B. Nabavi et al. / EBioMedicine 2 (2015) 1405–14192012) to 32.1% (95% CI 24.9–39.8) (Kauer-Sant'Anna et al., 2007). Meta-
analysis pooled prevalence of comorbid speciﬁc phobia was 10.8% (95%
CI 8.2–13.7) with high heterogeneity (Table 1 and Fig. 7).4.6. Lifetime Panic Disorder Comorbidity in Bipolar Disorder
We identiﬁed 46 relevant articles which including 1537 individuals
with lifetime panic disorder comorbidity in bipolar affective disorder
(Fig. 8). All studies were carried out in either psychiatric outpatient
clinics or inpatient settings. The lifetime prevalence of panic disorder
in individual studies ranged from 2.3% (95% CI 0.5–6.6) (Vieta et al.,
2001) to 54.2% (95% CI 43.7–64.4) (Okan Ibiloglu and Caykoylu,
2011). Meta-analysis pooled prevalence of comorbid panic disorder
was 16.8% (95% CI 13.7–20.1) with high heterogeneity (Table 1 and
Fig. 8).4.7. Lifetime OCD Comorbidity in Bipolar Disorder
We identiﬁed 43 relevant articles which including 808 individuals
with lifetime OCD comorbidity in bipolar affective disorder (Fig. 9). All
studies were carried out in either psychiatric outpatient clinics or inpa-
tient settings. The lifetime prevalence of OCD in individual studies
ranged from 1.4% (95% CI 0.8–2.3) (Azorin et al., 2009) to 38.5% (95%
CI 27.1–50.9) (TamamandOzpoyraz, 2002).Meta-analysis pooled prev-
alence of comorbid OCDwas 10.7% (95% CI 8.7–13.0) with high hetero-
geneity (Table 1 and Fig. 9).5. Discussion
To the best of our knowledge, there has been no previous meta-
analysis examining the lifetime prevalence of comorbidity between
Fig. 4. Lifetime PTSD comorbidity in bipolar disorder.
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variation in prevalence across studies was found by graphical represen-
tation of estimates and by indices of heterogeneity. Despite this wide
variation, pooled estimates are often useful to indicate the clinical bur-
den of the comorbidities. All original studies were carried out according
to interview-based methods of deﬁning bipolar disorder and anxiety
disorders, using comprehensive and fully structured tools, such as CIDI
and SCID-IV and were conducted by trained interviewers. In total, we
were able to identify 52 studies consisting of 13,656 individualswith bi-
polar affective disorder, for whom the lifetime comorbid anxiety disor-
ders had been examined (Table 2). Meta-analysis pooled prevalence of
the lifetime comorbidity of any anxiety disorders in 29 out of 52 studies
was 42.7% (95% CI 37.5–48.0). However, it is to be noted that the total
number of individuals with comorbid anxiety disorders was less than
the above number, as some individuals had more than one identiﬁed
anxiety disorder comorbidity. To examine the impact of single versusmultiple anxiety disorder comorbidities, Boylan et al. (2004) found no
signiﬁcant differences between the groups of patients with 1, 2, 3
or more anxiety disorders for any of the outcome measures (all
P values N 0.15).
Whenever possible, we only used the data for bipolar type I, as
some studies such as the Bridge Study (Angst et al., 2013) found
higher prevalence of lifetime comorbidity in type II (27.5% vs.
16.9%). Otherwise we only included the data when the authors clear-
ly reported no signiﬁcant differences in their ﬁndings between types
I and II.
We found the overall rate of anxiety disorders, as well as the type of
anxiety disorder in clinical samples varied widely. To explain such vari-
ety, we found no signiﬁcant differences in sampling settings as to be ei-
ther inpatient or outpatient. One explanation may be the cross-national
variability of the primary studies. Other suggested contributory factors
include having different methodological approaches, such as being
Fig. 5. Lifetime social anxiety disorder comorbidity in bipolar disorder.
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ment method used in diagnosis and evaluation of period or lifetime
prevalence.
Some of primary studies (Boylan et al., 2004; Angst et al., 2013;
Grabski et al., 2008) found GAD to be themost common comorbid anx-
iety disorder in bipolar disorder. However themajority of studies found
panic disorder as themost common comorbid anxiety disorder in bipo-
lar disorder (Okan Ibiloglu and Caykoylu, 2011; Shoaib and Dilsaver,
1995). Wittchen et al. (1994) reported strong lifetime comorbiditybetween GAD and affective disorder (mania 10.5%, major depression
62.4% and dysthymia 39.5%).
With regard to the effects of single vs. multiple comorbid anxiety
disorders, in a sample of 153 bipolar I inpatient cases, Ghoreishizadeh
et al. (2009) identiﬁed 43% rate of anxiety disorders with no signiﬁcant
relationship between anxiety disorders and the severity of bipolar dis-
order and the duration of hospitalisation. Their ﬁndingswere consistent
with the results of a study by Henry et al. (2003), but contrary to the re-
sults of some other studies (El-Mallakh and Holliﬁeld, 2008; Sharma
Fig. 6. Lifetime agoraphobia comorbidity in bipolar disorder.
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2006). Using a random effect meta-analysis in our pooled data, we
foundpanic disorder to be themost common comorbid anxiety disorder
in bipolar disorder: 16.8% (95% CI 13.7–20.1), followed by GAD and so-
cial anxiety disorder with a prevalence of 14.4% (95% CI 10.8–18.3) and
13.3% (95% CI 10.1–16.9), respectively. We also estimated the rate of
lifetime comorbidity between bipolar disorder and PTSD, speciﬁc pho-
bia, OCD and agoraphobia to be 10.8% (95% CI 7.3–14.9), 10.8% (95%
CI 8.2–13.7), 10.7% (95% CI 8.7–13.) and 7.8% (95% CI 5.2–11.0),
respectively.
Finally, in limited studies it has been suggested that the presence or
absence of any particular comorbid anxiety disorders may alter the pat-
tern and prognosis of bipolar disorder. For instance, Pini et al. (1997)
suggested three patterns in association with anxiety and affective
disorder: (i) GAD was found to be stronger associated with dysthymia
than bipolar or unipolar depression; (ii) panic disorder was found to
have a greater tendency to co-occur with bipolar disorder than with
dysthymia and possibly than with unipolar depression; (iii) social pho-
bia was less common in bipolar cases. Duffy et al. (2010) suggested a
staging model: anxiety disorders appear as an early manifestation of
psychopathology in high-risk youth who go on to develop bipolar
illness. Perugi et al. (2001) suggested that social phobia most often pre-
cedes mania and then resolves, while other comorbid anxiety disorders
tend to persist.
5.1. Strengths and Limitations
Based on our experience with previous meta-analyses, we acknowl-
edge that we may have missed studies and/or made data entry
errors. We encourage readers to inform us of any missing studies
or errors in the data. Updated lists of relevant studies and raw data
will be available from the authors. We note several limitations to this
analysis.1. Due to the large degree of variation across studies, the heterogeneity
and publication bias were present. It is possible that some studies
were not identiﬁed in the searches if they were not published in
mainstream journals. There may have been some time lag bias,
with smaller studies, or studies with unremarkable results, coming
through to publication slower than larger studies.
2. The included studies were of a variable quality. Although they all re-
ceived a high methodological quality score, their ﬁndings cannot be
easily compared or generalised. Prevalence studies have often used
different diagnostic instruments, sampling procedures, case deﬁni-
tions and time frames for the diagnoses (e.g. lifetime, six month
prevalence or current diagnoses), as well as different severity ratings
for diagnostic decisions (Weissman et al., 1989).
3. We acknowledge that the deﬁnitions of prevalence could vary slight-
ly across studies, typically relying on cross-sectional assessment at
different stages of the illness, and occasionally used convenience
sampling.
4. Lifetime prevalence rate in comparison to current or point preva-
lence usually provides a higher rate, as it comprises the proportion
of the population who have ever had the disease. In contrast, current
and period prevalence rate gives a ﬁgure at a single point or period in
time (Jekel et al., 2001).
5. Interviewmethods commonly underestimate the prevalence of anx-
iety disorders when compared with self-report scales. However, the
consensus is that interview is methodologically superior to self-
report, as it is objective and comparable between individuals,
which may reduce the rate of false positive.
6. Wewere unable to extractmany correlates of different anxiety disor-
ders because of limitations in the underlying dataset. It is unlikely
that it would ever be possible to measure and record all potentially
important covariates.
7. A further limitation was the scarcity of data for non-DSM deﬁned
anxiety disorders, as none of the studies used explicit ICD criteria.
Fig. 7. Lifetime speciﬁc phobia comorbidity in bipolar disorder.
1413B. Nabavi et al. / EBioMedicine 2 (2015) 1405–14198. Some criticism directed at the studies demonstrates how the associ-
ation of bipolar disorder with anxiety disorders are with regard to
the diagnostic criteria employed. For instance, in GAD, as well as in
PTSD, there are criteria which prevail over those of bipolar disorder
(Cox et al., 1990).
5.2. Clinical Implications
Previous studies suggest that patients with high anxiety scores were
more likely to havemade a suicide attempt. Since anxiety itself is related
to suicidal behaviour, anxiety symptoms in bipolar patients may be an
important risk factor for suicide (Weissman et al., 1989). Similarly, the
strong relationship between anxiety disorders and alcohol abuse (Cox
et al., 1990; Kushner et al., 1990) also suggest that bipolar patients
with high anxiety scores may be at risk of alcohol misuse. Kessler et al.
(1997) suggested a high comorbidity with substance misuse, includingalcohol in bipolar disorder could represent attempts to modulate the
mood liability associated with bipolar disorder or that they could be
symptoms of mood disturbance. Young et al. (1993) observed a trend
toward lithium non-responsiveness in his high anxiety group of pa-
tients. There is also some contradictory evidence between anxiety and
impulsivity in bipolar disorder. While some studies (Oosterlaan, 1998;
Pliszka et al., 1999; Brown, 2000; Manassas et al., 2000) found anxiety
as a protective factor for impulsiveness, others (Summmerfeldt et al.,
2004; Taylor et al., 2008) found it an aggravating factor.
With regard to the psychopharmacologic treatment of anxiety disor-
ders in bipolar disorder, in the absence of any robust evidenced-based
data, it will remain challenging and perhaps risky, particularly because
of the concern that antidepressants may destabilise mood in bipolar pa-
tients, and benzodiazepines are problematic in patients with comorbid
alcohol/substance use disorders. In the presence of bipolar disorder,
the ﬁrst choice of anxiolytic medication may be shifted towards a
Fig. 8. Lifetime panic disorder comorbidity in bipolar disorder.
1414 B. Nabavi et al. / EBioMedicine 2 (2015) 1405–1419
Fig. 9. Lifetime OCD comorbidity in bipolar disorder.
1415B. Nabavi et al. / EBioMedicine 2 (2015) 1405–1419medication covering both conditions, such as a typical or atypical anti-
psychotic. However, the effect of atypical antipsychotic (e.g. olanzapine,
quetiapine and lurasidone) on anxiety during bipolar depression shouldbe viewed with caution and as preliminary (Tohen et al., 2003;
Calabrese et al., 2005; Loebel et al., 2014a,b). It is also suggested that co-
morbid anxiety disorders can be effectively treated in bipolar patients
Table 2
Overview of prevalence studies of anxiety disorders in patients with bipolar disorder.
Authors Sampling methoda
Settingb
Qualityc Bias riskd No with bipolar
disorder
Mean age (years) Type of anxiety disorders Country
Angst et al. (2013) 1 IN/OP 4 1 685 44.1 GAD, SAD, AGR, PD, OCD, AD USA
Hernandez et al. (2013) 1 OP 4 1 3158 39.9 PTSD USA
Alvarez et al. (2012) 0 OP 4 1 40 39.4 PTSD Spain
Bellani et al. (2012) 1 OP 4 0 205 36.6 GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD USA
Castro e Couto et al. (2012) 1 OP 4 0 95 40.9 GAD, PD Brazil
Chang et al. (2012) 1 OP 4 1 120 31.4 GAD, PTSD, SAD, PD, SP, OCD, AD Taiwan
Dell'Osso et al. (2011) 0 OP 4 1 508 44.4 GAD, PD, OCD Italy
Saunders et al. (2012) 0 IN/OP 4 1 736 42.6 SAD, SP, PD, OCD, AD USA
Tsai et al. (2012) 0 OP 4 0 306 37.0 GAD, SAD, SP, AGR, PD, AD Taiwan
Fracalanza et al. (2011) 1 OP 4 0 62 40.0 GAD, PTSD, SAD, PD, OCD Canada
Okan Ibiloglu and Caykoylu (2011) 0 IN/OP 4 0 96 38.7 PTSD, SP, PD, OCD Turkey
Watson et al. (2011) 0 OP 4 0 165 39.5 AD Australia
Altshuler et al. (2010) 1 OP 4 1 711 41.9 PTSD, SAD, SP, PD, OCD, AD USA
Koyuncu et al. (2010) 0 OP 4 1 214 34.7 GAD, PTSD, SAD, SP, PD, OCD Turkey
Magalhães et al. (2010) 0 OP 4 0 259 41.6 OCD, AD Brazil
Mantere et al. (2010) 0 IN/OP 4 0 144 38.0 GAD, PTSD, SAD, SP, PD, OCD, AD Finland
Azorin et al. (2009) 0 IN 4 1 1090 43.0 GAD, PTSD, SAD, AGR, PD, OCD, PD France
Nery-Fernandes et al. (2009) 0 OP 4 1 62 42.0 GAD, PTSD, SAD, AGR, PD, OCD, PD Brazil
Grabski et al. (2008) 0 OP 4 0 73 44.6 GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD Poland
Ciapparelli et al. (2007) 0 OP 4 1 56 35.8 SAD, PD, OCD, AD Italy
Kauer-Sant'Anna et al. (2007) 0 OP 4 1 162 43.1 GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD Brazil
Levander et al. (2007) 1 OP 4 0 350 41.7 PTSD, SAD, SP, PD, OCD, AD USA
Simon et al. (2007) 1 OP 4 1 120 44.2 GAD, PTSD, SAD, AGR, PD, OCD, AD USA
Altindag Abdurrahman et al. (2006) 0 OP 4 1 70 34.7 GAD, SAD, SP, PD, PTSD Agoraphobia, OCD AD Turkey
Otto et al. (2006) 0 OP 4 0 918 40.6 GAD, PTSD, SAD, AGR, PD, OCD, AD USA
Pashinian et al. (2006) 0 OP 4 1 56 28.9 SAD, SP, PD, OCD Israel
Pini et al. (2006) 0 IN 4 1 189 33.5 SAD, PD, OCD Italy
Wilk et al. (2006) 0 OP 4 1 154 NR PD USA
Zutshi et al. (2006) 1 OP 4 1 80 30.0 GAD, SAD, PD, OCD, AD India
Bauer et al. (2005) 1 IN 4 0 328 46.6 PTSD, PD, OCD, AD USA
Boylan et al. (2004) 0 OP 4 0 138 42.0 GAD, PTSD, SAD, SP, PD, OCD, AD Canada
Simon et al. (2004) 1 OP 4 0 475 41.7 GAD, PTSD, SAD, AGR, PD, OCD, AD USA
Henry et al. (2003) 0 IN 4 1 318 53.3 PD, OCD, AD France
Pini et al. (2003) 0 IN 4 0 151 36.2 PD Italy
Simon et al. (2003) 1 OP 4 1 122 40.8 GAD, PTSD, SAD, SP, PD, OCD, AD USA
Craig et al. (2002) 1 IN/OP 4 0 138 NR PD, OCD USA
Tamam and Ozpoyraz (2002) 0 OP 4 1 70 33.4 GAD, PTSD, SAD, SP, PD, OCD, AD Turkey
Vieta et al. (2001) 0 OP 4 0 129 40.9 SAD, SP, PD, OCD Spain
Yerevanian et al. (2001) 0 OP 4 1 35 39.8 GAD, PTSD, SP, PD, OCD, AD USA
Krüger et al. (2000) 1 IN 4 1 143 44.0 GAD, SP, PD, OCD Germany
Cassano et al. (1999) 0 IN 4 1 48 33.5 SAD, PD, OCD Italy
Pini et al. (1999) 0 IN 4 0 125 24.7 GAD, SAD, SP, PD, OCD Italy
Cosoff and Hafner (1998) 0 IN 4 1 20 34.8 GAD, SAD, SP, PD, OCD, AD Australia
Strakowski et al. (1998) 0 IN 4 0 77 25.0 GAD, PTSD, SAD, SP, PD, OCD USA
Pini et al. (1997) 0 OP 4 0 24 37.9 GAD, SAD, SP, PD, OCD, AD Italy
Chen and Dilsaver (1995a,b) 0 OP 4 0 167 20.6 PD, OCD USA
Krüger et al. (1995) 1 IN 4 1 37 49.0 OCD Canada
Sharma et al. (1995) 0 IN/OP 4 1 25 37.8 GAD, SAD, SP, AGR, PD, OCD Canada
Shoaib and Dilsaver (1995) 0 IN 3 1 41 33.1 PD USA
Strakowski et al. (1995) 0 IN/OP 4 1 39 29.6 GAD, PTSD, OCD USA
Young et al. (1993) 0 OP 4 1 81 37.6 GAD, PD, AD Canada
Strakowski et al. (1992) 0 IN 4 1 41 31.6 SP, PD, OCD, AD USA
AD=anxiety disorders. GAD=generalised anxiety disorder. NR=not reported. OCD=obsessive compulsive disorder. PD=panic Disorder. PTSD=posttraumatic stress disorder. RDC=
research diagnostic criteria. SAD= social anxiety disorder. SP = simple phobia.
All studies used DSM (III, III-R, IV) criteria for the diagnoses of bipolar and anxiety disorders, except Young et al. (1993), using RDC (Research Diagnostic Criteria) criteria.
a 1 = convenience sample, 0 = consecutive sample.
b (IN) = Inpatient, (OP) = outpatient.
c 1 = low quality, 2 = low-to-medium quality, 3 = medium-to-high quality, 4 = high quality.
d 0 = no appreciable bias risk, 1 = low bias risk, 2 = low-to-medium bias risk, 3 = medium-to-high bias risk, and 4 = high bias risk.
1416 B. Nabavi et al. / EBioMedicine 2 (2015) 1405–1419using psychological interventions. There is some evidence in favour
of CBT (Baer et al., 1985; Bowen and D'Arcy, 2003; Hamblen et al.,
2004; Mueser et al., 2008; Mueser et al., 2007; Provencher et al.,
2010; Rosenberg et al., 2004) (Cognitive Behavioural Therapy), and
mindfulness-based cognitive therapy (Miklowitz et al., 2009; Williams
et al., 2008), in the treatment of anxiety comorbid to bipolar disorder.
On the other hand, interpersonal therapy (Frank et al., 2005) and family
therapy (Gaudiano andMiller, 2005)would not seem to offer any signif-
icant beneﬁt to this group. Finally, the co-occurrence of more than one
anxiety disorder in an individual may limit the utility of psychotherapy
in patients with bipolar disorder (Deckersbach et al., 2014).6. Conclusion
Interest in the co-occurrence of bipolar disorder and anxiety disor-
ders has grown markedly in the past two decades. Our results, in line
with previous studies, suggest that anxiety disorders co-occur frequent-
ly in patients with bipolar illness. However, it is unclear if this is an ex-
pression of the pathology of two independent and distinct disorders or
an additive interaction of the coexisting disorders.
More detailed information on the patterns of response to psycholog-
ical and psychopharmacological interventions among those with bipo-
lar disorder with or without anxiety disorders may be useful in further
1417B. Nabavi et al. / EBioMedicine 2 (2015) 1405–1419delineating the aetiological signiﬁcance (e.g. shared neurobiological
mechanisms) of the co-occurrence of bipolar disorder and anxiety dis-
orders. In addition, more in-depth examinations of the temporal rela-
tionship between the onset of bipolar disorder and anxiety disorders
using longitudinal designs may be helpful in understanding aetiology
and developing interventions that could delay or even prevent the
onset of bipolar disorder among those at high risk. The diagnostic issues
at the interface of affective and anxiety disorders are particularly
difﬁcult because of the substantial symptom overlap. Although some
advances have recently been made, the treatment of co-existing condi-
tions has clinically remained challenging. As with its companion studies
on the prevalence of comorbidities, we hope that the current review
will populate and generate the hypotheses. Paradoxes such as this can
be a powerful catalyst for advancing knowledge.
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